131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: Procedure guidelines for tumour imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 12, 2010, Pages 2436-2446

  Bombardieri, Emilio ^a   Giammarile, Francesco ^b   Aktolun, Cumali ^c   Baum, Richard P ^d   Bischof Delaloye, Angelika ^e   Maffioli, Lorenzo ^f   Moncayo, Roy ^g   Mortelmans, Luc ^h   Pepe, Giovanna ⁱ   Reske, Sven N ^j   Castellani, Maria R ^a   Chiti, Arturo ⁱ  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HOSPICES CIVILS DE LYON   (France)

^c Tiro Center Tiroid Merkezi   (Turkey)

^d PET Center   (Germany)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f Ospedale di Legnano   (Italy)

^g UNIVERSITY OF INNSBRUCK   (Austria)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j UNIVERSITY OF ULM   (Germany)

more..

Author keywords

Indications; Procedure guidelines; Tumour imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ADRENERGIC NEURON BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTITUSSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRETYLIUM; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; DECONGESTIVE AGENT; DILTIAZEM; GUANETHIDINE; INOTROPIC AGENT; LABETALOL; NEUROLEPTIC AGENT; OPIATE; PHENOXYBENZAMINE; RESERPINE; SEDATIVE AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VASOCONSTRICTOR AGENT; VERAPAMIL; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL PAIN; BREAST FEEDING; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; NEUROENDOCRINE TUMOR; PALLOR; PATIENT SAFETY; PRACTICE GUIDELINE; PREGNANCY; RADIATION DOSE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TACHYCARDIA; THYROID GLAND; TUMOR SCINTISCANNING; VOMITING; ARTICLE; NEOPLASM; NUCLEAR MEDICINE; ONCOLOGY; SCINTISCANNING; STANDARD;

3-IODOBENZYLGUANIDINE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; NUCLEAR MEDICINE; PRACTICE GUIDELINES AS TOPIC; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 78649777321     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1545-7     Document Type: Review

References (41)

1. M Nakajo B Shapiro J Copp, et al. 1983 The normal and abnormal distribution of the adrenomedullary imaging agent m-I123-iodobenzylguanidine (I-123 MIBG) in man: evaluation by scintigraphy J Nucl Med 24 672 682 1:CAS:528:DyaL3sXltFymtL4%3D 6135764
2. D Rubello C Bui D Casara 2002 Functional scintigraphy of the adrenal gland Eur J Endocrinol 147 13 28 1:CAS:528:DC%2BD38XlvVCksLw%3D 10.1530/eje.0.1470013 12088915
3. A Leung B Shapiro R Hattner, et al. 1997 The specificity of radioiodinated MIBG for neural crest tumors in childhood J Nucl Med 38 1352 1357 1:STN:280:DyaK2svjvVSisw%3D%3D 9293786
4. JC Sisson BL Shulkin 1999 Nuclear medicine imaging of pheochromocytoma and neuroblastoma Q J Nucl Med 43 217 223 1:STN:280:DC%2BD3c%2FjsVWgsA%3D%3D 10568137
5. B Shapiro MD Gross 1987 Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG Med Pediatr Oncol 15 170 177 1:STN:280:DyaL1c%2FhtlKhsw%3D%3D 10.1002/mpo.2950150406 3309602
6. E Bombardieri M Maccauro E De Deckere, et al. 2001 Nuclear medicine imaging of neuroendocrine tumours Ann Oncol 12 S51 S61 10.1023/A:1012488727716 11762353
7. Troncone L, Rufini V. Radiolabeled metaiodobenzylguanidine in the diagnosis of neural crest tumors. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone; 1998. p. 843-57.
8. Staalman CR, Hoefnagel CA. Imaging of neuroblastomas and metastasis. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, editors. neuroblastoma. Amsterdam: Elsevier; 2000. p. 303-29.
9. International Commission on Radiological Protection. Publication 80: Radiation dose to patients from radiopharmaceuticals. Annals of the ICRP, vol. 28. Oxford: Pergamon Press; 1998. p. 3.
10. MG Stabin MJ Gelfand 1998 Dosimetry of pediatric nuclear medicine procedures Q J Nucl Med 42 93 112 1:STN:280:DyaK1czmtVOktw%3D%3D 9695662
11. International Commission on Radiological Protection. Publication 53: Radiation dose to patients from radiopharmaceuticals. Annals of the ICRP, vol. 18. Oxford: Pergamon Press; 1987. p. 1-4.
12. A Boubaker A Bischof Delaloye 2003 Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy Q J Nucl Med 47 31 40 1:STN:280:DC%2BD3s7psFGgsw%3D%3D 12714952
13. Y Perel J Conway M Kletzel, et al. 1999 Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma J Pediatr Hematol Oncol 21 13 18 1:STN:280:DyaK1M7lsVSlug%3D%3D 10.1097/00043426-199901000-00004 10029806 (Pubitemid 29131988)
14. AR Wafelman CA Hoefnagel RA Maes, et al. 1994 Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interaction, cytotoxicity and dosimetry Eur J Nucl Med 21 545 559 1:CAS:528:DyaK2cXmsV2msLk%3D 10.1007/BF00173043 8082671
15. P Olivier P Colarinha J Fettich, et al. 2003 Guidelines for radioiodinated MIBG scintigraphy in children Eur J Nucl Med Mol Imaging 30 B45 B50 10.1007/s00259-003-1138-9 12658506
16. M Lassmann L Biassoni M Monsieurs C Franzius F Jacobs EANM Dosimetry and Paediatrics Committees 2007 The new EANM paediatric dosage card Eur J Nucl Med Mol Imaging 34 796 798 1:STN:280:DC%2BD2s3kvFKgsg%3D%3D 10.1007/s00259-007-0370- 0 17406866 (Pubitemid 46669372)
17. KK Solanki J Bomanji J Moyes, et al. 1992 A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG) Nucl Med Commun 13 513 521 1:CAS:528: DyaK38XmtVOqtb0%3D 10.1097/00006231-199207000-00006 1495678
18. FA Khafagi B Shapiro LM Fig, et al. 1989 Labetalol reduces iodine-131-MIBG uptake by pheochromocytoma and normal tissues J Nucl Med 30 481 489 1:STN:280:DyaL1M3ptlaqsQ%3D%3D 2738677
19. F Giammarile A Boneu V Edeline, et al. 2000 Guide de réalisation de la scintigraphie à la meta-iodobenzylguanidine (MIBG) en oncologie pédiatrique Med Nucl 24 35 41
20. EB Sokole A Plachcinska A Britten 2010 Routine quality control recommendations for nuclear medicine instrumentation Eur J Nucl Med Mol Imaging 37 662 671 10.1007/s00259-009-1347-y
21. GY Meyer-Rochow GP Schembri DE Benn MS Sywak LW Delbridge BG Robinson, et al. 2010 The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (mIBG SPECT/CT) for the diagnosis of pheochromocytoma Ann Surg Oncol 17 392 400 10.1245/s10434-009-0850-5 19949879
22. V Rufini GA Fisher BL Shulkin, et al. 1996 Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging J Nucl Med 37 1464 1468 1:STN:280:DyaK28zot1egsg%3D%3D 8790194
23. V Rufini A Giordano D Di Giuda, et al. 1995 123MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging Q J Nucl Med 4 25 28
24. MD Lynn B Shapiro JC Sisson, et al. 1984 Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123Iwiodobenzylguanidine: concise communication J Nucl Med 25 4 436 440 1:STN:280:DyaL28%2FmtFyntA%3D%3D 6544815
25. N Furuta H Kiyota F Yoshigoe N Hasegawa Y Ohishi 1999 Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy Int J Urol 6 3 119 124 1:STN:280:DyaK1M3ktlCjug%3D%3D 10.1046/j.1442-2042.1999.06310.x 10226821 (Pubitemid 30406825)
26. C Okuyama N Sakane T Yoshida K Shima H Kurosawa K Kumamoto, et al. 2002 (123)I- or (125)I-metaiodobenzylguanidine visualization of brown adipose tissue J Nucl Med 43 9 1234 1240 1:CAS:528:DC%2BD38Xns1els74%3D 12215564
27. L Peggi E Liberti G Pansini, et al. 1992 Pitfalls in scintigraphic detection of neuroendocrine tumors Eur J Nucl Med 19 214 218
28. I Gordon AM Peters A Gutman, et al. 1990 Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans J Nucl Med 31 129 134 1:STN:280:DyaK3c7ovVCqtw%3D%3D 2313350
29. N Ady JM Zucker B Asselain V Edeline F Bonnin J Michon, et al. 1995 A new 123I-MIBG whole body scan scoring method - application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma Eur J Cancer 31A 2 256 261 1:STN:280:DyaK2M3jsVCiuw%3D%3D 10.1016/0959-8049(94) 00509-4 7718334
30. A Suc J Lumbroso H Rubie JM Hattchouel A Boneu C Rodary, et al. 1996 Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system Cancer 77 4 805 811 1:STN:280:DyaK287os1ylug%3D%3D 10.1002/(SICI)1097-0142(19960215)77:4<805::AID-CNCR29>3.0.CO;2-3 8616776 (Pubitemid 26055409)
31. HM Katzenstein SL Cohn RM Shore DM Bardo PR Haut M Olszewski, et al. 2004 Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma J Clin Oncol 22 19 3909 3915 10.1200/JCO.2004.07.144 15459212 (Pubitemid 41079872)
32. JA Messina SC Cheng BL Franc M Charron B Shulkin B To, et al. 2006 Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma Pediatr Blood Cancer 47 7 865 874 10.1002/pbc.20777 16444675 (Pubitemid 44656106)
33. BG Taal CA Hoefnagel Valdes Olmos, et al. 1996 Combined diagnostic imaging with 131I-MIBG and 111In-pentetreotide in carcinoid tumours Eur J Cancer 32 1924 1932 10.1016/0959-8049(96)00241-9 (Pubitemid 26361686)
34. JM Zuetenhorst CA Hoefnagel H Boot, et al. 2002 Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease Nucl Med Commun 23 735 741 1:CAS:528:DC%2BD38Xmslejs7o%3D 10.1097/00006231-200208000-00006 12124478 (Pubitemid 34837003)
35. S Adams R Baum T Rink, et al. 1998 Limited value of fluorine- 18fluoodeoxyglucose PET for the imaging of neuroendocrine tumours Eur J Nucl Med 25 79 83 1:CAS:528:DyaK2sXnvVGru7o%3D 10.1007/s002590050197 9396878 (Pubitemid 28107907)
36. DR Taggart MM Han A Quach S Groshen W Ye JG Villablanca, et al. 2009 Comparison of iodine-123 metaiodobenzylguanidine (mIBG) scan and [18F]FDG positron emission tomography to evaluate response after iodine-131 mIBG therapy for relapsed neuroblastoma J Clin Oncol 27 5343 5349 1:CAS:528: DC%2BD1MXhsFKkt7rL 10.1200/JCO.2008.20.5732 19805691
37. BH Kushner HW Yeung SM Larson K Kramer NK Cheung 2001 Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography as sole imaging modality in follow-up of patients J Clin Oncol 19 3397 3405 1:STN:280: DC%2BD3MvgtlKnug%3D%3D 11454888
38. SE Sharp BL Shulkin MJ Gelfand S Salisbury 2010 123I-mIBG versus 18F-FDG in neuroblastoma: which is better, or which can be eliminated? J Nucl Med 51 331 10.2967/jnumed.109.070003
39. SE Sharp BL Shulkin MJ Gelfand S Salisbury WL Furman 2009 123I-mIBG scintigraphy and 18F-FDG PET in neuroblastoma J Nucl Med 50 1237 1243 10.2967/jnumed.108.060467 19617326
40. HJLM Timmers CC Chen JA Carrasquillo M Whatley A Ling B Havekes, et al. 2009 Comparison of 18F-fluoro-l-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-mIBG scintigraphy in the localization of pheochromocytoma and paraganglioma J Clin Endocrinol Metab 94 4757 4767 1:CAS:528:DC%2BD1MXhsFyltLbJ 10.1210/jc.2009-1248 19864450
41. RJ Ott D Tait MA Flower JW Babich RM Lambrecht 1992 Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography Br J Radiol 65 787 791 1:STN:280:DyaK3s%2Fgs12jtw%3D%3D 10.1259/0007-1285-65-777-787 1393416